[go: up one dir, main page]

EP1763503A1 - 4-t-butylgabapentin and its synthesis - Google Patents

4-t-butylgabapentin and its synthesis

Info

Publication number
EP1763503A1
EP1763503A1 EP05732985A EP05732985A EP1763503A1 EP 1763503 A1 EP1763503 A1 EP 1763503A1 EP 05732985 A EP05732985 A EP 05732985A EP 05732985 A EP05732985 A EP 05732985A EP 1763503 A1 EP1763503 A1 EP 1763503A1
Authority
EP
European Patent Office
Prior art keywords
trans
cis
butylgabapentin
mixture
gabapentin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05732985A
Other languages
German (de)
French (fr)
Inventor
Nagarajan Hikal Limited KUPPUSWAMY
Sivaramakrishnan Hikal Limited HARIHARAN
Venkatachalam Shankar Hikal Limited IYER
Suresh Babu Hikal Limited BALAKRISHNAN
Gopalakrishnan Hikal Limited KRISHNAMURTHI
Ananda Molecular Biophysics Unit KUPPANA
Muruga P. R. Molecular Biophysics Unit KARUPPIAH
Balaram Molecular Biophysics Unit PADMANABHAN
Aravinda Department of Physics SUBRAYASHASTRY
Gouriamma Vasudev Department of Physics PREMA
Shamala Department of Physics NARAYANASWAMY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indian Institute of Science IISC
Hikal Ltd
Original Assignee
Indian Institute of Science IISC
Hikal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Institute of Science IISC, Hikal Ltd filed Critical Indian Institute of Science IISC
Priority to EP09012856A priority Critical patent/EP2172445A1/en
Publication of EP1763503A1 publication Critical patent/EP1763503A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to stereo isomers (E) and (Z) of 4-t-butyl gabapentin and a process for the preparation of the said stereoisomers.
  • Gabapentin, (1-aminomethyl) eye lohexane-1 -acetic acid is an antiepileptic drug, which has been found to have pain-relieving properties. Additionally, it is claimed to have anti-anxiety activity as also beneficial properties in treating neuro- degenerative diseases like Alzheimer's. Gabapentin and its analogues are reported to exert their activity by binding to the alpha 2-delta sub unit of calcium channel.
  • WO 99/14184 reports the synthesis of gabapentin analogues 3-methyl, 4- methyl and 3,5-dimethyl gabapentin and their biological activity.
  • the aminomethyl group could preferentially occupy the equatorial position in the more stable conformation along with certain percentage in the axial position.
  • the exact conformation in which these bind to a receptor is not known. If the energy differences are not significant, binding with the aminomethyl group in the axial position cannot be ruled out.
  • This document does not claim the report of t-butyl gabapentin specifically but covers it in a generic way.
  • the tertiary butyl group has been known as an anchoring substituent on the cyclohexane ring occupying exclusively the equatorial confirmation in the ring. Therefore, if one were to synthesize 1-aminomethyl cyclohexane- 1 -acetic acids with a 4-t-butyl group in cis or trans stereochemistry with respect to the aminomethyl group to obtain Z and E stereoisomer respectively it should be feasible to study better, the optimal conformation for good binding of 4-t-butyl gabapentin with the alpha 2 delta sub unit of the calcium channel.
  • prior art search revealed the report of 4-t-butyl gabapentin in documents US 6103932 and WO 02/00347 A2.
  • US 6103932 recites and claims 4-t- butyl gabapentin, and a pharmaceutically acceptable salts thereof or a prodrug thereof, while WO 2002/00347A 2 notes the use of t-bmylgabapentin in the form of a prodrug without any example.
  • the document also describes general synthetic methods for the preparation of alkyl gabapentin analogues having one or more alkyl substituents in the cyclohexane ring. There is no specific example describing the preparation of the compound 4-t-butylgabapentin.
  • This patent also records the radio ligand-binding assay with the alpha 2 detla sub unit derived from porcine brain tissue giving an IC50 value of 200micro M for 4-t-butyl gabapentin, again without stereochemistry, thus missing out a solution to the crucial and challenging issue of conformational identity in the native and bound states.
  • US 6103932 describe various synthetic routes for the preparation gabapentin analogues where as WO 99/14184 restricts itself to the use of a nitro methyl intermediate to obtain gabapentin analogues.
  • an alkyl substituted cyclohexanone is treated with ethyl cyanoacetate and ammonia gas in methanol to afford a dicyano spiroglutarimide which is hydrolysed by hot concentrated sulphuric acid to an alkyl substituted cyclohexane- 1,1- diacetic acid.
  • the diacid is converted to the anhydride, which is opened up with methanol to give the half-ester acid.
  • This is treated with ethyl chloroformate followed by sodium azide.
  • Thermolysis of the acyLazide gives an isocyanate which upon hydrolysis with concentrated hydrochloric acid yields the alkyl substituted gabapentin hydrochloride.
  • WO 99/14184 the method adopted is to add nitrometha.ne to an alkyl substituted cyclohexylidene acetic ester, which upon catalytic reduction affords the alkyl-substituted azaspirodecanone. Hydrolysis with 6 N HC1 and evaporation affords the alkyl substituted gabapentin hydrochloride.
  • US Patent No 6103932 and PCT Int'l Application publication WO 99/14184 describe examples wherein the final products, gabapentin analogues are obtained only as hydrochloride salts.
  • 4-t-butyl gabapentin which can bind with the alpha2delta.
  • Objects of the Invention is to report pure forms Z(cis) and E(trans) stereoisomers of 4-t-butylgabapentin.
  • Another object of the present invention is to synthesize EZ mixture of 4-t- butylgabapentin, separate the mixture into pure stereoisomers and characterize them by using physical methods, namely, IR, high field proton NMR and single crystal X-ray crystallography.
  • Yet another object of the invention is to provide Z and E stereoisomers of 4-t- butylgabapentin and its pharmaceutically acceptable salts as an agent for the treatment of neurodegenerative disorders.
  • Description of the accompanied diagram Fig 1 depicts schematic expression of the preparation of cis and trans isomers of 4-t-butylgabapentin.
  • the present invention provides a report of cis(Z) and trans(E) stereoisomers of 4-t-butylgabapentin and process for their preparation in high purity.
  • the process for the preparation of the cis and trans isomer of 4-t- butylgabapentin has been achieved, as outlined in Fig I.
  • 4-t-Butyl-cyclohexanone (I) was treated with ethylcyano acetate and ammonia in methanol to yield ammonium salt of dicyanoimide (2) .
  • Hydrolysis of (2) with hot sulfuric acid afforded the diacid (3) which was converted to the anhydride (4).
  • stereoisomers and its pharmaceutically acceptable salts of the present invention can be used as an agent for the treatment of neurodegenerative disorders.
  • a pharmaceutical composition comprising an effective amount of these compounds may be used for the treatment.
  • the present invention is illustrated with following example and should not be construed to limit the scope of the invention.
  • Step-1 Preparation of ammonium salt of l,5-dicyano-2,4-dioxo-9-t-butyl-3- azaspiroundecane (2) 204 gms (1.32 mole) of 4-t-butyl cyclohexanone and 299.3 gms (2.64 mole) of ethyl cyano acetate were mixed, cooled to -5°C and treated with 640 ml of 15% wt/vol methanolic ammonia (pre-cooled to -5°C) at -5° to 0°C, slowly over a period
  • Step-2 Preparation of 4-t-butylcyclohexyl-l,l-diacetic acid (3) 300 ml of 60% sulphuric acid (wt/vol) was heated to 125-130°C. 89 gms of the ammonium salt (2) of step (1) was added in small portions to the hot sulphuric acid mixture at about 125-130°C. During the addition of the salt, the reaction was exothermic and at the end of the addition which was completed over a period of 3 hrs, the temperature was allowed to rise up to 140°C. The reaction mixture was maintained at 130-140°C for 15 hrs. Then it was cooled to 25-30°C and the ash coloured solid was filtered.
  • Step-3 Preparation of 4-t-butylcyclohexyl-l,l-diaceticacid monoamide (5) 28.8 gms of 4-t-butyl cyclohexyl- 1,1 -diacetic acid (3) was refluxed with 47.7 gms(0.6 mole) of freshly distilled acetyl chloride for 3 hrs .
  • the volatiles were distilled at around 80°C in water bath under vacuum to obtain as anhydride (4) which was quenched in 100 ml of aqueous ammonia.
  • the resultant aqueous ammonia was stirred for 30 minutes at 25-30°C and washed with toluene to remove neutral impurities.
  • the purified ammonium salt solution was acidified to pH 1-2 with concentrated HC1.
  • the solid precipitated was filtered and dried at 60-70 °C to get 4-t-butyl cyclohexyl-1,1- diacetic acid mono amide (5), mp: 176-180°C.
  • Step-4 Preparation of 8-t-butyl-azaspiro [4,5]-undecan-3-one (6)
  • 15.68 gms (0.39 mole) of sodium hydroxide was dissolved in 110.5 ml of water and chilled to 0 - -5°C.
  • To this 12.86 gms (0.08 mole) of bromine was added over 30 min. followed by 20 gms of (5) which was added in several lots at 0 to -5°C.
  • the reaction mixture was stirred at the same temperature for 30 min. It was then heated slowly over an hour to 80 -85°C, and the temperature maintained at 80-85°C for 6 hr.
  • Step-5 Preparation of t-butylgabapentin hydrochloride (8) 2 gms of t-butylgabalactam (6) (0.009 mole) was heated with 5 ml of concentrated HC1 at 95-100°C forl ⁇ hrs. The resultant clear solution was cooled to 70°C when a solid separated; 5 ml toluene was added, the mixture further cooled to 30°C and filtered to get t-butyl gabapentin hydrochloride. The aqueous portion of the mother liquor was separated and heated to 95-100°C for 8 hr. The clear solution, was cooled and 5 ml toluene was added.
  • Step-6 Preparation of 4-t-butylgabapentin (10) 2 gms of (0.0076 mole) of 4-t-butylgabapentin hydrochloride (8) was dissolved in 4 ml water. The clear solution was heated to 45- 50 °C, treated with charcoa.1 and filtered. The filtrate was neutralized with 10% sodium hydroxide solution to jpH 7. The solid precipitate was filtered and was washed with 2ml water. The wet product was warmed with 10 ml of methanol, filtered at room temperature and dried to afford the mixture of cis and trans 4-t-butyl- gabapentin (10); mp 176 - 180°C.
  • Step-7 Preparation of E and Z isomers of 4-t-butyl gabapentin Compound (10) on crystallization from MeOH/EtOH/H2O yielded two forms of conformational isomers Z and E designated as (11) and (12) respectively.
  • Z(ll),mpl83-184°C E(12),mpl82-183°C The structures of (11) and (12) were determined by NMR and X-ray diffraction data.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds cis (Z) and trans (E) stereoisomers of 4-t-butylgapentin of formula (11) and (12) and a process for the preparation of the said stereoisomers.

Description

4-T-BUTY GABAPENTIN AND ITS SYNTHESIS
Technical Field The present invention relates to stereo isomers (E) and (Z) of 4-t-butyl gabapentin and a process for the preparation of the said stereoisomers. Background and Prior art reference Gabapentin, (1-aminomethyl) eye lohexane-1 -acetic acid is an antiepileptic drug, which has been found to have pain-relieving properties. Additionally, it is claimed to have anti-anxiety activity as also beneficial properties in treating neuro- degenerative diseases like Alzheimer's. Gabapentin and its analogues are reported to exert their activity by binding to the alpha 2-delta sub unit of calcium channel. WO 99/14184 reports the synthesis of gabapentin analogues 3-methyl, 4- methyl and 3,5-dimethyl gabapentin and their biological activity. In all these analogues the aminomethyl group could preferentially occupy the equatorial position in the more stable conformation along with certain percentage in the axial position. However the exact conformation in which these bind to a receptor is not known. If the energy differences are not significant, binding with the aminomethyl group in the axial position cannot be ruled out. This document does not claim the report of t-butyl gabapentin specifically but covers it in a generic way. The tertiary butyl group has been known as an anchoring substituent on the cyclohexane ring occupying exclusively the equatorial confirmation in the ring. Therefore, if one were to synthesize 1-aminomethyl cyclohexane- 1 -acetic acids with a 4-t-butyl group in cis or trans stereochemistry with respect to the aminomethyl group to obtain Z and E stereoisomer respectively it should be feasible to study better, the optimal conformation for good binding of 4-t-butyl gabapentin with the alpha 2 delta sub unit of the calcium channel. However, prior art search revealed the report of 4-t-butyl gabapentin in documents US 6103932 and WO 02/00347 A2. US 6103932 recites and claims 4-t- butyl gabapentin, and a pharmaceutically acceptable salts thereof or a prodrug thereof, while WO 2002/00347A 2 notes the use of t-bmylgabapentin in the form of a prodrug without any example. The document also describes general synthetic methods for the preparation of alkyl gabapentin analogues having one or more alkyl substituents in the cyclohexane ring. There is no specific example describing the preparation of the compound 4-t-butylgabapentin. This patent also records the radio ligand-binding assay with the alpha 2 detla sub unit derived from porcine brain tissue giving an IC50 value of 200micro M for 4-t-butyl gabapentin, again without stereochemistry, thus missing out a solution to the crucial and challenging issue of conformational identity in the native and bound states. US 6103932 describe various synthetic routes for the preparation gabapentin analogues where as WO 99/14184 restricts itself to the use of a nitro methyl intermediate to obtain gabapentin analogues. In the former patent, two routes are employed:, (a) an alkyl-substiruted cyclohexanone is converted to a cyanocyclohexylidene acetic ester, which is treated with aqueous alcoholic sodium cyanide to 1-cyanocyclohexane acetic ester, which upon reduction gives an azaspirodecanone. Hydrolysis of the lactam with 1 : 1 HC1 affords the aJkyl substituted gabapentin hydrochloride. In the second route, an alkyl substituted cyclohexanone is treated with ethyl cyanoacetate and ammonia gas in methanol to afford a dicyano spiroglutarimide which is hydrolysed by hot concentrated sulphuric acid to an alkyl substituted cyclohexane- 1,1- diacetic acid. The diacid is converted to the anhydride, which is opened up with methanol to give the half-ester acid. This is treated with ethyl chloroformate followed by sodium azide. Thermolysis of the acyLazide gives an isocyanate which upon hydrolysis with concentrated hydrochloric acid yields the alkyl substituted gabapentin hydrochloride. In WO 99/14184, the method adopted is to add nitrometha.ne to an alkyl substituted cyclohexylidene acetic ester, which upon catalytic reduction affords the alkyl-substituted azaspirodecanone. Hydrolysis with 6 N HC1 and evaporation affords the alkyl substituted gabapentin hydrochloride. US Patent No 6103932 and PCT Int'l Application publication WO 99/14184 describe examples wherein the final products, gabapentin analogues are obtained only as hydrochloride salts. Thus, in order to establish the optimal conformation for the compound 4-t-butyl gabapentin, which can bind with the alpha2delta. subunit of the calcium channel, it is necessary to obtain cis and trans form of 4-t-fc>utylgabapentin with high purity. There are prior art references on gabapentin analogues wifJh one or more methyl groups in the cyclohexane ring and publications on their binding activity. The ascertainment of the precise conformation in which the amino group in gabapentin binds to the alpha2delta subunit can have great significance in the design of newer analogues of gabapentin and more specifically alkyl gabapentin analogues None of the prior art document reports cis and trans stereoisomers of 4-t-butylgabapentin and their process of preparation.
Objects of the Invention Main object of the invention is to report pure forms Z(cis) and E(trans) stereoisomers of 4-t-butylgabapentin. Another object of the present invention is to synthesize EZ mixture of 4-t- butylgabapentin, separate the mixture into pure stereoisomers and characterize them by using physical methods, namely, IR, high field proton NMR and single crystal X-ray crystallography. Yet another object of the invention is to provide Z and E stereoisomers of 4-t- butylgabapentin and its pharmaceutically acceptable salts as an agent for the treatment of neurodegenerative disorders. Description of the accompanied diagram Fig 1 depicts schematic expression of the preparation of cis and trans isomers of 4-t-butylgabapentin.
Description of the invention In accordance with the objects, the present invention provides a report of cis(Z) and trans(E) stereoisomers of 4-t-butylgabapentin and process for their preparation in high purity. The process for the preparation of the cis and trans isomer of 4-t- butylgabapentin has been achieved, as outlined in Fig I. 4-t-Butyl-cyclohexanone (I) was treated with ethylcyano acetate and ammonia in methanol to yield ammonium salt of dicyanoimide (2) . Hydrolysis of (2) with hot sulfuric acid afforded the diacid (3) which was converted to the anhydride (4). (4) treated with aqueous ammonia to give the mono-amide (5) as a mixture containing approximately equal proportions of stereoisomers.. Reaction of (5) with sodium hypobromite solution led to the formation of lactam (6) as a mixture of stereoisomers [proton NMR (7) and its isomer with NCH2 axial in the ratio of 3:2] from which one of the isomer could be crystallized out in pure form from methanol-hexane, mp 176-7°C and its structure identified as (7) by NMR and single crystal X-ray analysis ( Hydrolysis of lactam (6) with hot concentrated HC1 gave a mixture of isomers of 4-t-butyl gabapentin hydrochloride (8). Crystallization of (8) from water afforded in pure form, mp 146-147°C, the isomer hemihydrate (9) with aminomethyl group in the anxial position. Dissolution of (8) in water followed by neutralization with aqueous NaOH to pH 7 precipitated the free-amino acid, surprisingly in good yield, a mixture of stereoisomers of 4-t-butyl gabapentin (10). Obviously the much poorer water solubility of (10) compared to the other gabapentin analogues is due to the presence of the more lipophilic t-butyl group. Fractional crystallization of (10) from methanol water allowed the separation of pure crystals of the Z stereoisomer (11) (Cis amino methyl ) mp 183-184°C and E-stereoisomer (12) (trans amino methyl ) mp 182-183 of 4-t-butyl gabapentin to which structural assignments were made by high field proton NMR and X-ray diffraction.
The stereoisomers and its pharmaceutically acceptable salts of the present invention can be used as an agent for the treatment of neurodegenerative disorders. A pharmaceutical composition comprising an effective amount of these compounds may be used for the treatment. The present invention is illustrated with following example and should not be construed to limit the scope of the invention. Example Preparation of Z(cis) and E(trans) stereoisomers of 4-t-butyl gabapentin:
Step-1 Preparation of ammonium salt of l,5-dicyano-2,4-dioxo-9-t-butyl-3- azaspiroundecane (2) 204 gms (1.32 mole) of 4-t-butyl cyclohexanone and 299.3 gms (2.64 mole) of ethyl cyano acetate were mixed, cooled to -5°C and treated with 640 ml of 15% wt/vol methanolic ammonia (pre-cooled to -5°C) at -5° to 0°C, slowly over a period
90minutes. The combined mixture was stirred for 1 hour and refrigerated at -5° to 0°C for a time period 96 hr. A thick product was formed and was filtered and washed with 100 ml of chilled methanol and dried to get the ammonium salt of l,5-dicyano-2,4- dioxo-9-t-butyl-3-azaspiroundecane (2) ; mp 238 - 240°C.
Step-2 Preparation of 4-t-butylcyclohexyl-l,l-diacetic acid (3) 300 ml of 60% sulphuric acid (wt/vol) was heated to 125-130°C. 89 gms of the ammonium salt (2) of step (1) was added in small portions to the hot sulphuric acid mixture at about 125-130°C. During the addition of the salt, the reaction was exothermic and at the end of the addition which was completed over a period of 3 hrs, the temperature was allowed to rise up to 140°C. The reaction mixture was maintained at 130-140°C for 15 hrs. Then it was cooled to 25-30°C and the ash coloured solid was filtered. This crude diacid was washed with 200 ml of water. Then the wet product was suspended in 300 ml of 20%) ammonia solution, warmed and filtered over a bed of hyflo supercel. The clear filtrate was acidified with concentrated HC1 to get pure 4-t-butylcyclohexyl-l,l-diaceticacid(3), which was dried at 60-70°C; mp l78 - 183°C.
Step-3 Preparation of 4-t-butylcyclohexyl-l,l-diaceticacid monoamide (5) 28.8 gms of 4-t-butyl cyclohexyl- 1,1 -diacetic acid (3) was refluxed with 47.7 gms(0.6 mole) of freshly distilled acetyl chloride for 3 hrs .The volatiles were distilled at around 80°C in water bath under vacuum to obtain as anhydride (4) which was quenched in 100 ml of aqueous ammonia. The resultant aqueous ammonia was stirred for 30 minutes at 25-30°C and washed with toluene to remove neutral impurities. The purified ammonium salt solution was acidified to pH 1-2 with concentrated HC1. The solid precipitated was filtered and dried at 60-70 °C to get 4-t-butyl cyclohexyl-1,1- diacetic acid mono amide (5), mp: 176-180°C.
Step-4 Preparation of 8-t-butyl-azaspiro [4,5]-undecan-3-one (6) 15.68 gms (0.39 mole) of sodium hydroxide was dissolved in 110.5 ml of water and chilled to 0 - -5°C. To this 12.86 gms (0.08 mole) of bromine was added over 30 min. followed by 20 gms of (5) which was added in several lots at 0 to -5°C. The reaction mixture was stirred at the same temperature for 30 min. It was then heated slowly over an hour to 80 -85°C, and the temperature maintained at 80-85°C for 6 hr. The reaction mixture was now cooled to 25-30°C and extracted with 300 ml of ethylene dichloride (EDC). The aqueous layer was again heated to 80-85°C, cooled and extracted with 300 ml of EDC. Both EDC layers were combined and distilled to obtain a mixture of stereoisomeres of t-butylgabalactam (6), m.p 150-154°C, which was almost white in colour. Crystallization of (6) from methanol-hexane gave one of the isomer (7) in pure form mp 176- 177°C.
5 6
Step-5 Preparation of t-butylgabapentin hydrochloride (8) 2 gms of t-butylgabalactam (6) (0.009 mole) was heated with 5 ml of concentrated HC1 at 95-100°C forlόhrs. The resultant clear solution was cooled to 70°C when a solid separated; 5 ml toluene was added, the mixture further cooled to 30°C and filtered to get t-butyl gabapentin hydrochloride. The aqueous portion of the mother liquor was separated and heated to 95-100°C for 8 hr. The clear solution, was cooled and 5 ml toluene was added. The solid formed again was filtered to get aiLother crop of the t-butylgabapentin hydrochloride. Both the crops were combined and stirred with 10 ml of acetone for 30 min. The product was filtered to get 4-t-butylgabap»entin hydrochloride (8) as a mixture of cis and trans isomers, m.p 172-1S0°C. Crystallization from water gave one of the isomer (9) in the pure form as a hemihydrate; mp 146-147°C.
6 8 Step-6 Preparation of 4-t-butylgabapentin (10) 2 gms of (0.0076 mole) of 4-t-butylgabapentin hydrochloride (8) was dissolved in 4 ml water. The clear solution was heated to 45- 50 °C, treated with charcoa.1 and filtered. The filtrate was neutralized with 10% sodium hydroxide solution to jpH 7. The solid precipitate was filtered and was washed with 2ml water. The wet product was warmed with 10 ml of methanol, filtered at room temperature and dried to afford the mixture of cis and trans 4-t-butyl- gabapentin (10); mp 176 - 180°C.
10
Step-7 Preparation of E and Z isomers of 4-t-butyl gabapentin Compound (10) on crystallization from MeOH/EtOH/H2O yielded two forms of conformational isomers Z and E designated as (11) and (12) respectively. Z(ll),mpl83-184°C E(12),mpl82-183°C The structures of (11) and (12) were determined by NMR and X-ray diffraction data.

Claims

I / We claim (1) Compounds cis (Z) and trans (E) stereoisomers of 4-t-butylgabapentin of formula (11) and (12)
and its pharmaceutically acceptable salts thereof. (2) A process for the preparation of compounds of claim 1, said process comprising steps of:
(a) contacting 4-t-butylethyl cyclohexanol (1) with cyanoacetate and ammonia in a solvent preferably methanol at a temperature ranging between 0° to 5°C for a period of up to 96h to obtain ammonium salt of dicyanoimide (2),
(b) hydrolyzing ammonium salt of dicyanoimide
(2) of step (a) with hot sulfuric acid at a temperature ranging between 125° to 140°C for a period of 3h to yield diacid (3),
(c) converting diacid (3) of step (b) to its anhydride (4), by quenching in aqueous ammonia, washing with aromatic hydrocarbon solvent, preferably toluene to obtain monoamide (5),
(d) treating monoamide (5) with aqueous sodium hypobromite solution by gradually raising the temperature from -5°Cto 85°C over a period of an hour, maintaining the temperature for about further 6h, cooling to 25°to30°C, extracting with haloalkane solvent, preferably ethylenedichloride to obtain (cis, trans) mixture of lactam (6), (e) hydrolyzing lactam (6) with concentrated hydrochloric acid at a temperature ranging between 95° and 100°C to obtain (cis, trans) mixture of 4-t-butylgabapentin hydrochloride (8),
(f) neutralizing aqueous solution of compound (8) after treating with charcoal followed by alkali to pH.7.0 to obtain (cis, trans) mixture of 4-t- butylgabapentin (10), and
(g) crystallizing compound (10) from a mixture of methanol-ethanol-water to obtain pure form of stereoisomers Cis (Z) and trans (E). of 4-t- butylgabapentin (11) and (12).
(3) An intermediate compound of formula (5)
SCHEME I
(4)
(5) (6)
(8) (10)
12
EP05732985A 2004-03-17 2005-03-16 4-t-butylgabapentin and its synthesis Withdrawn EP1763503A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09012856A EP2172445A1 (en) 2004-03-17 2005-03-16 Cis (z) 4-t-butylgabapentin and its synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55356504P 2004-03-17 2004-03-17
PCT/IN2005/000082 WO2005087709A1 (en) 2004-03-17 2005-03-16 4-t-butylgabapentin and its synthesis

Publications (1)

Publication Number Publication Date
EP1763503A1 true EP1763503A1 (en) 2007-03-21

Family

ID=47227360

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09012856A Withdrawn EP2172445A1 (en) 2004-03-17 2005-03-16 Cis (z) 4-t-butylgabapentin and its synthesis
EP05732985A Withdrawn EP1763503A1 (en) 2004-03-17 2005-03-16 4-t-butylgabapentin and its synthesis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09012856A Withdrawn EP2172445A1 (en) 2004-03-17 2005-03-16 Cis (z) 4-t-butylgabapentin and its synthesis

Country Status (3)

Country Link
EP (2) EP2172445A1 (en)
CA (1) CA2570255A1 (en)
WO (1) WO2005087709A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116345A (en) * 2019-12-30 2020-05-08 上海华理生物医药股份有限公司 Novel method for preparing Mirogabalin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (en) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
DK0888285T3 (en) 1996-03-14 2002-04-08 Warner Lambert Co Novel bridged cyclic amino acids as pharmaceutical agents
BR9812351A (en) 1997-09-18 2000-09-19 Warner Lambert Co New stereoselective process for the preparation of analogous gabapentins
AU7024801A (en) 2000-06-28 2002-01-08 3M Innovative Properties Co Enhanced sample processing devices, systems and methods
EP1404324B2 (en) * 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005087709A1 *

Also Published As

Publication number Publication date
WO2005087709A1 (en) 2005-09-22
EP2172445A1 (en) 2010-04-07
CA2570255A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
JP2839344B2 (en) Method for producing cyclic amino acid and intermediate thereof
US7632864B2 (en) Gabapentin analogues and process thereof
KR101532570B1 (en) Compounds useful in the synthesis of benzamide compounds
EA013819B1 (en) Amino-methyl substituted tetracycline compounds
NZ248842A (en) Aralkyl(thio)amides, preparation and pharmaceutial compositions
AU2006250207B2 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
US20050209332A1 (en) Gabapentin analogues and process thereof
EP2172445A1 (en) Cis (z) 4-t-butylgabapentin and its synthesis
US2466177A (en) Hydantoins and method fob obtaining
KR101327866B1 (en) Improved process for preparing Mitiglinide calcium salt
KR100957725B1 (en) Method for preparing intermediate of cilastatin
US2098954A (en) Hydrouracil compounds and processes for their production
JP2948923B2 (en) Method for producing retinoic acid and its isomer
CA3180417A1 (en) Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
JP4699582B2 (en) Method for producing 1H-4 (5) -aminoimidazole-5 (4) -carboxamide
JP2013119518A (en) Method for producing (s)-2-benzyl-3-(cis-hexahydro-2-isoindonilylcarbonyl)benzyl propionate
EP1599446A1 (en) An improved process for the preparation of gabalactam
CN113582902A (en) Preparation method of brivaracetam and intermediate thereof
JP2821700B2 (en) Method for producing 4-amino-cis-2-buten-1-ol
JPH06340623A (en) Production of benzylsuccinic acid derivative and intermediate for its synthesis
KR20090010546A (en) Method for preparing gabapentin and intermediates
CN107778307B (en) Preparation method of central alpha 2 adrenoreceptor agonist
EP1513819A1 (en) Process for preparing (s)-tetrahydro-a-(1-methylethyl)-2-oxo-1(2h)- pyrimidineacetic acid
KR790001021B1 (en) Process for preparing sulfonamide
CN114634422A (en) Preparation method of dinitolmide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20090630

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131001